This site is intended for healthcare professionals
Photo of Prostate cancer cells under microscope, pink and purple tones.
Prostate Cancer Nexus

Arun Azad

Last updated: 11th Feb 2026
Published: 11th Feb 2026

Alex Wyatt

Arun Azad, MBBS, FRACP, PhD

Arun Azad is Professor of Medical Oncology at the University of Melbourne and a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre in Melbourne, Australia. Azad has served in leadership roles across multiple international clinical trial steering committees. He is the Translational Chair of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group and Urologic Oncology Chair at the Clinical Oncology Society of Australia. He also contributes to international standards of care as a member of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines Committee for prostate cancer.

Disclosures: Honoraria from Aculeus Therapeutics, Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Janssen, Merck Serono, Merck Sharpe Dohme, Novartis, Noxopharm, Pfizer, Sanofi, Telix, and Tolmar. Member of scientific advisory board for Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Daiichi Sankyo, Ipsen, Janssen, Merck Serono, Merck Sharpe Dohme, Novartis, Noxopharm, Pfizer, Sanofi, Telix, and Tolmar. Travel and accommodation support from Amgen, Astellas, Bayer, Hinova, Janssen, Merck Serono, Novartis, Pfizer, and Tolmar. Research funding from Aptevo Therapeutics (institutional), Astellas (investigator), Astellas (institutional), AstraZeneca (institutional), AstraZeneca (investigator), Bayer (institutional), Bionomics (institutional), Bristol Myers Squibb (institutional), Eli Lilly (institutional), Exelixis (institutional), Gilead Sciences (institutional), GlaxoSmithKline (institutional), Hinova (institutional), Ipsen (institutional), Janssen (institutional), MedImmune (institutional), Merck Serono (investigator), Merck Serono (institutional), Merck Sharpe Dohme (institutional), Novartis (institutional), Pfizer (institutional), Sanofi (institutional), and SYNthorx (institutional). Member of steering committee for AstraZeneca, Arvinas, Astellas, Exelixis, Janssen, Pfizer, and Merck Sharpe Dohme.

View content featuring Azad:

Overcoming barriers to HRR testing

Complete the form below to receive our regular round-up of the latest clinical news and medical education resources on Medthority, straight to your inbox.

* = required information 

 

By providing your email address, you are opting in to receive our monthly newsletter.

By submitting this form you agree to our Terms of Use and Privacy Policy. You can withdraw your consent at any time by clicking the ‘unsubscribe’ link found at the bottom of every email.

Welcome: